BPG BPG Beratungs- und Prüfungsgesellschaft mbH
blau-gelber Hintergrund

Crowe advises Ethypharm on the acquisition of the Argatroban business from Mitsubishi Tanabe Pharma Corporation, a Mitsubishi Chemical Group company

Advisory

Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a Mitsubishi Chemical Group company, to acquire the selective antithrombin agent argatroban monohydrate in Europe. The drug is currently available in 13 countries, including Germany, the UK, France, Spain and Italy, and is used in the treatment of heparin-induced thrombocytopenia type II (HIT type II).

Ethypharm is a leading mid-sized international pharmaceutical company with 1700 employees, a presence in 68 countries and headquarters in France. The company specializes in the treatment of diseases of the central nervous system and in the manufacture of essential medicines.

BPG Beratungs- und Prüfungsgesellschaft mbH (Crowe BPG), led by Dr. Philipp Kruse, StB and Managing Director, advised the buyer on all tax aspects.

Source: Deal Advisors by Majunke

Cookie-Settings